AbbVie Move Against Data Transparency | Reuters Events | Pharma
Adalimumab - Wikipedia
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study - Yamasaki - 2020 - The Journal of Dermatology - Wiley Online Library
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - Gastroenterology
First clinical trial with D2E7 (Humira) - YouTube
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
Humira, INN - adalimumab
Humira Biosimilars Clinical Trial Insight - Research and Markets
Phase III clinical trials conducted for adalimumab biosimilars; data... | Download Scientific Diagram
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text
Taking Citrate-Free Humira: What Patients Need to Know
![PDF] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial](https://d3i71xaburhd42.cloudfront.net/1f3ea24e842b7750dfbe6b098b7b1b52e074980f/5-Figure1-1.png "PDF] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial")
PDF] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
VARSITY Ulcerative Colitis Clinical Trial | Entyvio® (vedolizumab)
Trial Of Usability in Clinical settings of HUMIRA autoinjector versus... | Download Scientific Diagram
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis | NEJM
Safety | Crohn's Disease (CD) | HUMIRA® (adalimumab)
AbbVie's Humira sales continue to climb beyond its patent expiration - Clinical Trials Arena
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Annals of the Rheumatic Diseases
Abbvie initiates new clinical trial to evaluate humira® (adalimumab) for the treatment of fingernail psoriasis - Drug Target Review
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
Safety | Crohn's Disease (CD) | HUMIRA® (adalimumab)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial - Journal of the American Academy of Dermatology
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
BioSpace Feature: A Look at Miracle Drug Humira's Journey to Proven Efficacy | BioSpace
HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA)
